Valuation: Pelthos Therapeutics Inc.

Market Cap 102M 88.83M 83.17M 76.08M 144M 9.75B 146M 973M 382M 4.87B 384M 376M 16.21B P/E 2026 *
-2.52x
P/E 2027 * -16.2x
Enterprise Value 102M 88.83M 83.17M 76.08M 144M 9.75B 146M 973M 382M 4.87B 384M 376M 16.21B EV / Sales 2026 *
1.6x
EV / Sales 2027 * 0.84x
Free-Float
46.22%
Yield 2026 *
-
Yield 2027 * -
1 day+3.19%
1 week+12.19%
Current month+2.76%
1 month+21.04%
3 months+17.80%
6 months+28.10%
Current year-5.00%
1 week 26.22
Extreme 26.22
29.52
1 month 24.48
Extreme 24.48
29.52
Current year 18.19
Extreme 18.19
30.99
1 year 16.5
Extreme 16.5
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Sell

Director

-558 0.0161%
7/2/26 Sell

Director

-786 0.0226%
7/2/26 Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
+3.19%+12.19%+47.10% - 99.19M
+1.89%+3.20%+59.70%+165.18% 1,043B
-0.24%+0.45%+50.64%+52.02% 621B
-0.95%-5.26%+24.23%+65.08% 435B
0.00%+3.20%+46.70%+37.60% 361B
+0.58%-1.26%+35.52%+40.54% 293B
-1.55%-6.84%+7.20%+8.62% 251B
-0.73%+4.44%+42.22%+66.41% 220B
-0.24%-11.27%+1.42%-44.69% 201B
-0.68%-0.32%+18.66%+66.32% 164B
Average -0.15%-1.31%+33.34%+50.79% 358.92B
Weighted average by Cap. -0.54%-1.42%+40.67%+77.18%

Financials

2026 *2027 *
Net sales 63.92M 55.47M 51.94M 47.51M 89.69M 6.09B 90.86M 608M 238M 3.04B 240M 235M 10.13B 121M 105M 98.47M 90.08M 170M 11.54B 172M 1.15B 452M 5.77B 455M 445M 19.2B
Net income -41.39M -35.92M -33.63M -30.76M -58.08M -3.94B -58.83M -393M -154M -1.97B -155M -152M -6.56B -6.74M -5.85M -5.48M -5.01M -9.46M -642M -9.58M -64.06M -25.14M -321M -25.3M -24.75M -1.07B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
26-08-06 US$29.45 +3.19% 75,780
26-08-05 US$28.54 +6.89% 59,723
26-08-04 US$26.70 -0.52% 132,726
26-08-03 US$26.84 -6.35% 374,480
26-07-31 US$28.66 +9.18% 324,265
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
29.45USD
Average target price
57.71USD
Spread / Average Target
+95.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock